NCT03029338View on ClinicalTrials.gov

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

May 22, 2019

Study Completion Date

June 22, 2021

Conditions
Lymphomas Non-Hodgkin's B-CellRelapse
Interventions
BIOLOGICAL

CD19 CAR T cells

CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER